WO2002018335A1 - Cyclic amine derivatives - Google Patents

Cyclic amine derivatives Download PDF

Info

Publication number
WO2002018335A1
WO2002018335A1 PCT/JP2001/007321 JP0107321W WO0218335A1 WO 2002018335 A1 WO2002018335 A1 WO 2002018335A1 JP 0107321 W JP0107321 W JP 0107321W WO 0218335 A1 WO0218335 A1 WO 0218335A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclic amine
amine derivatives
optionally substituted
group
ccr3
Prior art date
Application number
PCT/JP2001/007321
Other languages
French (fr)
Japanese (ja)
Inventor
Koichiro Morihira
Hiroshi Inami
Hirokazu Kubota
Kazuhiro Yokoyama
Tatsuaki Morokata
Makoto Takeuchi
Toshiya Takahashi
Masayuki Kaneko
Takayuki Imaoka
Yuichi Torii
Yosuke Iura
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd., Toray Industries, Inc. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to AU2001280187A priority Critical patent/AU2001280187A1/en
Publication of WO2002018335A1 publication Critical patent/WO2002018335A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Saturated cyclic amine derivatives each bearing a CH2-D group on the nitrogen atom and a specific group containing a carbocycle or a heterocycle on one of the carbon atoms, or salts thereof (wherein D is optionally substituted aryl, an optionally substituted heterocyclic group, or optionally substituted cycloalkyl). These compounds are useful in the treatment for CCR3-related diseases.
PCT/JP2001/007321 2000-08-28 2001-08-27 Cyclic amine derivatives WO2002018335A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001280187A AU2001280187A1 (en) 2000-08-28 2001-08-27 Cyclic amine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000257451 2000-08-28
JP2000-257451 2000-08-28

Publications (1)

Publication Number Publication Date
WO2002018335A1 true WO2002018335A1 (en) 2002-03-07

Family

ID=18745906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/007321 WO2002018335A1 (en) 2000-08-28 2001-08-27 Cyclic amine derivatives

Country Status (2)

Country Link
AU (1) AU2001280187A1 (en)
WO (1) WO2002018335A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089418A1 (en) * 2002-04-16 2003-10-30 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents
WO2004022535A1 (en) * 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. Acrylamide derivatives
WO2004045518A2 (en) * 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004054581A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
FR2854158A1 (en) * 2003-04-25 2004-10-29 Sanofi Synthelabo New 2-phenylcarbonylamino-4-phenyl-thiazole derivatives, useful for treating e.g. immunoinflammatory diseases and angiogenesis, are inhibitors of chemokine receptors
WO2005033102A2 (en) * 2003-10-03 2005-04-14 Amphora Discovery Corporation Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
WO2005108359A1 (en) * 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
WO2006028284A1 (en) 2004-09-08 2006-03-16 Mitsubishi Pharma Corporation Morpholine compound
JP2006514926A (en) * 2002-11-12 2006-05-18 アボット・ラボラトリーズ Bicyclic substituted amines as histamine-3 receptor ligands
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2008011392A2 (en) * 2006-07-20 2008-01-24 Ligand Pharmacueticals Incorporated Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2009016048A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7541369B2 (en) 2002-03-13 2009-06-02 Janssen Pharmaceutica, Nv Amino-derivatives as novel inhibitors of histone deacetylase
US7576103B2 (en) 2004-12-21 2009-08-18 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US20100197673A1 (en) * 2007-08-17 2010-08-05 Lg Life Sciences Ltd Indole and indazole compounds as an inhibitor of cellular necrosis
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
ES2350548A1 (en) * 2009-06-25 2011-01-25 Institut Univ. De Ciencia I Tecnologia, S.A. 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
WO2014084330A1 (en) * 2012-11-30 2014-06-05 協和発酵キリン株式会社 Nitrogen-containing heterocyclic compound
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2019226490A1 (en) * 2018-05-22 2019-11-28 Gilead Sciences, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US11618747B2 (en) 2018-06-28 2023-04-04 Orsobio, Inc. LXR modulators with bicyclic core moiety
US11970484B2 (en) 2018-06-28 2024-04-30 Orsobio, Inc. LXR modulators with bicyclic core moiety

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505868A (en) * 1992-03-31 1995-06-29 グラクソ、グループ、リミテッド Substituted phenyl carbamates and ureas
JPH08198751A (en) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd Carbamate derivative
WO2000076514A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505868A (en) * 1992-03-31 1995-06-29 グラクソ、グループ、リミテッド Substituted phenyl carbamates and ureas
JPH08198751A (en) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd Carbamate derivative
WO2000076514A1 (en) * 1999-06-11 2000-12-21 Merck & Co., Inc. Cyclopentyl modulators of chemokine receptor activity

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US8394831B2 (en) 2002-03-13 2013-03-12 Janssen Pharmaceutica, N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US7541369B2 (en) 2002-03-13 2009-06-02 Janssen Pharmaceutica, Nv Amino-derivatives as novel inhibitors of histone deacetylase
US9556161B2 (en) 2002-03-13 2017-01-31 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7476742B2 (en) 2002-04-16 2009-01-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents
WO2003089418A1 (en) * 2002-04-16 2003-10-30 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7799786B2 (en) 2002-06-28 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
WO2004022535A1 (en) * 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. Acrylamide derivatives
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
JP2006514926A (en) * 2002-11-12 2006-05-18 アボット・ラボラトリーズ Bicyclic substituted amines as histamine-3 receptor ligands
JP4820094B2 (en) * 2002-11-12 2011-11-24 アボット・ラボラトリーズ Bicyclic substituted amines as histamine-3 receptor ligands
WO2004045518A3 (en) * 2002-11-15 2004-10-07 Bristol Myers Squibb Co Open chain prolyl urea-related modulators of androgen receptor function
WO2004045518A2 (en) * 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7589207B2 (en) 2002-12-13 2009-09-15 Smithkline Beecham Corporation Cyclohexyl compounds as CCR5 antagonists
WO2004054581A3 (en) * 2002-12-13 2005-02-03 Smithkline Beecham Corp Cyclohexyl compounds as ccr5 antagonists
WO2004054581A2 (en) * 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US7777041B2 (en) 2003-04-25 2010-08-17 Sanofi-Aventis 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
US7504511B2 (en) 2003-04-25 2009-03-17 Sanofi-Aventis 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
FR2854158A1 (en) * 2003-04-25 2004-10-29 Sanofi Synthelabo New 2-phenylcarbonylamino-4-phenyl-thiazole derivatives, useful for treating e.g. immunoinflammatory diseases and angiogenesis, are inhibitors of chemokine receptors
WO2004096798A2 (en) * 2003-04-25 2004-11-11 Sanofi-Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
WO2004096798A3 (en) * 2003-04-25 2006-01-26 Sanofi Aventis Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and use of same as chemokine antagonists
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005033102A2 (en) * 2003-10-03 2005-04-14 Amphora Discovery Corporation Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
WO2005033102A3 (en) * 2003-10-03 2005-07-28 Amphora Discovery Corp Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7989640B2 (en) 2004-02-04 2011-08-02 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
WO2005108359A1 (en) * 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US9636341B2 (en) 2004-07-28 2017-05-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
WO2006028284A1 (en) 2004-09-08 2006-03-16 Mitsubishi Pharma Corporation Morpholine compound
US7576103B2 (en) 2004-12-21 2009-08-18 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US9078896B2 (en) 2006-01-19 2015-07-14 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2008011392A2 (en) * 2006-07-20 2008-01-24 Ligand Pharmacueticals Incorporated Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
WO2008011392A3 (en) * 2006-07-20 2008-05-22 Pharmacopeia Inc Proline urea ccr1 antagonists for the treatment of autoimmune diseases or inflammation
US8389507B2 (en) 2007-07-27 2013-03-05 Hoffmann-La Roche Inc. 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands
JP2010534701A (en) * 2007-07-27 2010-11-11 エフ．ホフマン−ラ ロシュ アーゲー 2-azetidine methanamine and 2-pyrrolidine methanamine as TAAR ligands
WO2009016048A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US9000028B2 (en) 2007-08-17 2015-04-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US20100197673A1 (en) * 2007-08-17 2010-08-05 Lg Life Sciences Ltd Indole and indazole compounds as an inhibitor of cellular necrosis
US9062052B2 (en) 2008-04-23 2015-06-23 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8785449B2 (en) 2008-04-23 2014-07-22 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8871770B2 (en) 2008-04-23 2014-10-28 Rigel Pharmaceuticals Inc. Carboxamide compounds and methods for using the same
US9255085B2 (en) 2008-04-23 2016-02-09 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9353111B2 (en) 2008-04-23 2016-05-31 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9796664B2 (en) 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
ES2350548A1 (en) * 2009-06-25 2011-01-25 Institut Univ. De Ciencia I Tecnologia, S.A. 1-(sulfonyl)-n-phenylpyrrolidine-2-carboxamides for the identification of biological and pharmacological activity
US9908899B2 (en) 2011-02-28 2018-03-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10280182B2 (en) 2011-02-28 2019-05-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9512143B2 (en) 2011-02-28 2016-12-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10981933B2 (en) 2011-02-28 2021-04-20 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10526346B2 (en) 2011-02-28 2020-01-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10301323B2 (en) 2011-02-28 2019-05-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
CN104995173A (en) * 2012-11-30 2015-10-21 协和发酵麒麟株式会社 Nitrogen-containing heterocyclic compound
US9701689B2 (en) 2012-11-30 2017-07-11 Kyowa Hakko Kirin Co., Ltd. Substituted pyridines and pyridazines as CCR10 receptor inhibitors
WO2014084330A1 (en) * 2012-11-30 2014-06-05 協和発酵キリン株式会社 Nitrogen-containing heterocyclic compound
JPWO2014084330A1 (en) * 2012-11-30 2017-01-05 協和発酵キリン株式会社 Nitrogen-containing heterocyclic compounds
US10428028B2 (en) 2013-03-15 2019-10-01 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
USRE47193E1 (en) 2013-10-14 2019-01-08 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US11866422B2 (en) 2016-06-21 2024-01-09 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11136290B2 (en) 2018-05-22 2021-10-05 The Liver Company Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
JP2021524856A (en) * 2018-05-22 2021-09-16 ギリアード サイエンシーズ， インコーポレイテッド Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
TWI732219B (en) 2018-05-22 2021-07-01 美商基利科學股份有限公司 Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
CN112204008A (en) * 2018-05-22 2021-01-08 吉利德科学公司 Sulphonylaminobenzylamide and sulphonylaminobenzamide derivatives
AU2019272538B2 (en) * 2018-05-22 2022-08-25 Orsobio, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
JP7158500B2 (en) 2018-05-22 2022-10-21 ザ リバー カンパニー インコーポレイテッド Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
WO2019226490A1 (en) * 2018-05-22 2019-11-28 Gilead Sciences, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
US11618747B2 (en) 2018-06-28 2023-04-04 Orsobio, Inc. LXR modulators with bicyclic core moiety
US11970484B2 (en) 2018-06-28 2024-04-30 Orsobio, Inc. LXR modulators with bicyclic core moiety

Also Published As

Publication number Publication date
AU2001280187A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
WO2002018335A1 (en) Cyclic amine derivatives
WO2001032654A3 (en) Novel heterocyclic compounds and their use as medicines
PT1178967E (en) QUINOLINE DERIVATIVES AS MEK ENZYMES INHIBITORS
DK0646115T3 (en) Heterocyclic / cyclic amine derivatives
ECSP055809A (en) 4-OXO-1- (3-REPLACED PHENYL) INHIBITORS -1,4-DIHYDRO-1,8-NAFTIRIDINA-3-CARBOXAMIDE OF PHOSPHODIESTERASE-4
DK0976748T3 (en) Pyrrolidine derivatives with phospholipase A2 inhibitory activity
DE68920632T2 (en) Antiamnesic pyrrolidine derivatives.
DK0445731T3 (en) Azabicyclo and azacyclooxime and amine cholinergic agents and pharmaceutically acceptable salts thereof
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
NO20052023L (en) Calcium activated K channel opens with high conductance
ES2126075T3 (en) NITROGENATED BICYCLE DERIVATIVES AS PROPIL-ENDOPEPTIDASE INHIBITORS.
DE69427517T2 (en) Tetracyclic condensed heterocyclic compounds for the treatment of senile dementia
NO981658D0 (en) Condensed piperidine compound
DE69329084T2 (en) Benzoxazepine derivatives as cholinesterase inhibitors
HK1001974A1 (en) Pharmaceutical piperazine compounds
HK1047096A1 (en) Taxane derivatives and processes for the preparation thereof.
NZ517315A (en) New derivatives of A-500359
AU5566300A (en) Acylhydrazine derivatives, process for preparing the same and use thereof
HUP9901417A2 (en) Condensed 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
ATE279191T1 (en) TRICYCLIC DIHYDROBENZOFURANES, METHOD FOR THE PRODUCTION THEREOF AND MEANS
NO994104L (en) 5-hydroxymethyl-2-aminotetralins in the form of cardiovascular agents
NO984547L (en) New oxazolidine derivatives, processes for their preparation, and drugs containing these compounds
ATE286728T1 (en) USE OF HOMOCYSTEINE DERIVATIVES TO TREAT BACTERIAL INFECTIONS
EP1145713A4 (en) Telomerase inhibitors
DE60014915D1 (en) HYPOXANTHIN AND THIOHYPXANTHIN COMPOUNDS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 523453

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase